Microlax micro enema 5 ml # 4 (for children from 0 to 3 years old )

Dosage form

Colorless, opalescent, viscous liquid.

Release form

Solution for rectal administration, 5 ml in microclysters for single use (polyethylene tube) - 4 pcs per pack.

Structure

One ml of solution contains:

Active substances: sodium citrate - 90 mg, sodium lauryl sulfoacetate 70% - 12.9 mg (corresponds to 9 mg of sodium lauryl sulfoacetate), sorbitol solution 70% - 893 mg (corresponds to 625 mg of sorbitol)

Excipients: sorbic acid - 1 mg, glycerol - 125 mg, purified water up to 1 ml.

pharmachologic effect

MICROLAX® is a combined drug with a laxative effect.

The effect occurs in 5-15 minutes.

The preparation contains sodium citrate (a peptizing agent that displaces bound water contained in feces), sodium lauryl sulfoacetate (dilutes the contents of the intestine) and sorbitol (enhances the laxative effect by stimulating the flow of water into the intestine).

An increase in the amount of water due to peptization and liquefaction promotes softening of feces and facilitates bowel movement.

Side effects

According to spontaneous reports of adverse events

Adverse reactions arising from the use of the drug, which were identified during the post-registration period, were classified as follows: very frequent (more than or equal to 10%), frequent (more than or equal to 1%, but < 10%), not frequent (more or equal to 0.1%, but < 1%), rare (more than or equal to 0.01%, but < 0.1%), very rare (< 0.01%) and adverse reactions with an unknown frequency of occurrence (frequency of occurrence cannot be estimated from the available data).

Disorders from the gastrointestinal tract.

Very rare: pain in the abdomen (including abdominal discomfort, pain in the abdomen, and also in the upper abdomen)

discomfort in the anorectal region, loose stools.

Immune system disorders.

Very rare: hypersensitivity reactions (eg, urticaria).

Selling features

Available without a prescription

Special conditions

If symptoms persist, avoid prolonged use and consult a doctor.

If the medicinal product has become unusable or the expiration date has expired, do not pour it into waste water or throw it out into the street!

Place the medicine in a bag and put it in the trash can.

These measures will help protect the environment!

Influence on the ability to drive vehicles and control mechanisms:

MICROLAX® does not affect the ability to drive vehicles and operate mechanisms.

Indications

Constipation, incl.

with encopresis, preparation for endoscopic (rectoscopy) and X-ray examination of the gastrointestinal tract.

Contraindications

Increased individual sensitivity to drug components.

Application during pregnancy and during breastfeeding:

There are no adequate and well-controlled studies in pregnant women.

Since this drug is probably only insignificantly absorbed into the systemic circulation, when used as recommended during pregnancy or lactation, adverse effects on the fetus or nursing child are not expected.

Drug interactions

There is a risk of developing colon necrosis with simultaneous oral / rectal administration of sodium polystyrene sulfonate and sorbitol, which is part of the drug.

Dosage

Newborns and children under 3 years old

Inject the entire contents of one micro enema rectally by inserting the universal tip halfway through (see the mark on the tip, see Fig. 1 for instructions in the package).

If the complaints persist for a long time, you should consult a doctor.

For children under 3 years old, it is also possible to use microclysters with a shortened tip (shortened length

Name ENG

MICROLAX

Clinical and pharmacological group

Laxative drug

ATX code

Sodium lauryl sulfoacetate (including in combination with other drugs)

Dosage

12.9mg / ml + 90mg / ml + 893mg / ml x 5ml

Structure

One ml of solution contains: Active substances: sodium citrate - 90 mg, sodium lauryl sulfoacetate 70% - 12.9 mg (corresponds to 9 mg sodium lauryl sulfoacetate), sorbitol solution 70% - 893 mg (corresponds to 625 mg of sorbitol)

Excipients: sorbic acid - 1 mg, glycerol - 125 mg, purified water up to 1 ml.

Indications

Constipation (including with encopresis)

preparation for endoscopic (rectoscopy) and X-ray examination of the gastrointestinal tract.

Contraindications

Increased individual sensitivity to the components of the Microlax preparation.

INN / Active ingredient

sodium lauryl sulfoacetate, sorbitol, sodium citrate

Storage conditions and periods

At a temperature not higher than 25 degrees.

Expiration date: 5 years

Specifications

Category

Laxatives

Scope of the medicinal product

Gastrointestinal tract

Release form

Solution

Manufacturer country

France

Package quantity, pcs

4

Scope of application

Gastroenterology

Minimum age from

From birth

Way of introduction

Rectally

Vacation conditions

Without recipe

Brand name

Famar Orleans

The amount of the dosage form in the primary package

5 ml

Primary packaging type

Microclysters

Type of consumer packaging

Pack of cardboard

Pharmaco-therapeutic group

Laxative

Dosage form

Rectal solution

The target audience

Children

Expiration date in days

1825

Package weight, g

thirty

Mode of application

:

Infants and children under 3 years of age < br> Introduce the entire contents of one micro enema rectally by inserting the universal tip halfway (see the mark on the tip, see Fig. 1 for instructions in the package). < br> If the complaints persist for a long time, you should consult a doctor. < br> For children under 3 years old, it is also possible to use microclysters with a shortened tip (the length of the shortened tip is 47.3 mm - see Fig. 2 instructions in the package). < br> In this case, it is necessary to enter the entire contents of one micro enema rectally, inserting the tip to its full length. < br> Directions for use: < br> Break off the seal on the tip of the tube. < br> Press lightly on the tube so that the drop of the drug smears the tip of the enema - this will facilitate the administration process. < br> Squeezing the tube,squeeze out its entire contents. < br> Remove the tip while still squeezing the tube slightly.

Anatomical and therapeutic characteristics

:

A06AG11 Lauryl sulfate, including in combination with other drugs

Dosage (volume) of the substance in the preparation

:

sodium citrate - 90 mg, sodium lauryl sulfoacetate 70% - 12.9 mg (corresponds to 9 mg of sodium lauryl sulfoacetate), sorbitol solution 70% - 893 mg (corresponds to 625 mg of sorbitol)

Information on technical characteristics, delivery set, country of manufacture